Saxonov Serge, CEO, reported a transaction classified as exercise at 10x Genomics, Inc. involving 50000.000000 shares for an estimated $60000.00. Reported holdings after the transaction were 921540.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 12, 2024 and terminated effective March 4, 2025.
This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide…
The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.
0 other filings
0 recent txs